“By the year 2004, it is expected that the value of the total western European
 

 
generics sector may have risen to $19 billion, representing almost 15% of allpharmaceuticals.
 

 


 

 
In the USA, the value of the generics sector is predicted to rise to $18.5 billion
 

 
in that time.

 

 
Overall, the total value of the global generics market by 2004 will probably be
 

 
in the region of $45 billion.”

 

 
The Generics Outlook 2001

 

 


 

 


 

 


 

 
The cyclical generics industry is once again on the upswing, following a period
 

 
of destructive price wars, driven by consolidation amongst drug distributors.
 

 


 

 
Real growth in the sector is outpacing growth in the pharmaceutical market and
 

 
penetration into new therapeutic markets is deepening.

 

 


 

 
The branded industry's reliance on blockbuster drugs and the impending patent
 

 
expiry of many top brands, including biotechnology products, presents the generics
 

 
sector with a multi-billion dollar opportunity over the near-term.

 

 
The Generics Outlook 2001 provides you with the most current data and analysis
 

 
to harness this growing opportunity in the generic marketplace.

 

 


 

 
By focusing on both sides of the market, The Generics Outlook 2001 highlights
 

 
the strategies of generics manufacturers as well as showing the branded sector's
 

 
response.

 

 


 

 


 

 


 

 
5 Reasons why you should buy this report today:

 

 


 

 
1. Understand the dynamics of drug demand by examining details of patients base
 

 
and epidemiological trends.

 

 


 

 
2. Realise the main factors affecting the future evolution of the generics market.
 

 
As well as blockbuster drugs, biotechnology products are now reaching the end
 

 
of their patent protected life.

 

 


 

 
3. Assess competitor and brand positioning and plan reaction to future competition
 

 
and new marketing challenges.

 

 


 

 
4. Understand the legal and regulatory issues within this industry and how they
 

 
affect your company.

 

 


 

 
5. Identify company trends and strategies and realise the areas of unmet need

Chapter 1: Introduction

Chapter 2: Key generic markets

Chapter 3: Emerging national emerging markets

Chapter 4: Generic markets by therapy area

Chapter 5: Regulatory issues

Chapter 6: Intellectual property (IP) issues

Chapter 7: Industry trends

Chapter 8: Making the generics voice heard

Chapter 9: Company profiles

Chapter 10: Appendix